Step climbing capacity in patients with pulmonary hypertension

被引:11
作者
Fox, Benjamin Daniel [1 ,2 ,3 ]
Langleben, David [1 ,2 ]
Hirsch, Andrew [1 ,2 ]
Boutet, Kim [1 ,2 ,4 ]
Shimony, Avi [1 ,2 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Ctr Pulm Vasc Dis, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[3] Tel Aviv Univ, Rabin Med Ctr, Pulm Inst, Petah Tiqwa, Israel
[4] Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ, Canada
关键词
Exercise pathophysiology; Exercise testing; Monitoring; Oxygen desaturation; Pulmonary arterial hypertension; Pulmonary hypertension; 6-MINUTE WALK TEST; LUNG RESECTION CANDIDATES; EXERCISE OXIMETRY TEST; ARTERIAL-HYPERTENSION; CARDIOPULMONARY EXERCISE; OXYGEN-CONSUMPTION; DISEASE;
D O I
10.1007/s00392-012-0495-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with pulmonary hypertension (PH) typically have exercise intolerance and limitation in climbing steps. To explore the exercise physiology of step climbing in PH patients, on a laboratory-based step test. We built a step oximetry system from an 'aerobics' step equipped with pressure sensors and pulse oximeter linked to a computer. Subjects mounted and dismounted from the step until their maximal exercise capacity or 200 steps was achieved. Step-count, SpO(2) and heart rate were monitored throughout exercise and recovery. We derived indices of exercise performance, desaturation and heart rate. A 6-min walk test and serum NT-proBrain Natriuretic Peptide (BNP) level were measured. Lung function tests and hemodynamic parameters were extracted from the medical record. Eighty-six subjects [52 pulmonary arterial hypertension (PAH), 14 chronic thromboembolic PH (CTEPH), 20 controls] were recruited. Exercise performance (climbing time, height gained, velocity, energy expenditure, work-rate and climbing index) on the step test was significantly worse with PH and/or worsening WHO functional class (ANOVA, p < 0.001). There was a good correlation between exercise performance on the step and 6-min walking distance-climb index (r = -0.77, p < 0.0001). The saturation deviation (mean of SpO(2) values < 95 %) on the step test correlated with diffusion capacity of the lung (rho = -0.49, p = 0.001). No correlations were found between the step test indices and other lung function tests, hemodynamic parameters or NT-proBNP levels. Patients with PAH/CTEPH have significant limitation in step climbing ability that correlates with functional class and 6-min walking distance. This is a significant impediment to their daily activities.
引用
收藏
页码:51 / 61
页数:11
相关论文
共 24 条
[1]  
Bland JM, 1996, BRIT MED J, V312, P1079
[2]   Peak Oxygen Consumption Measured during the Stair-Climbing Test in Lung Resection Candidates [J].
Brunelli, Alessandro ;
Xiume, Francesco ;
Refai, Majed ;
Salati, Michele ;
Di Nunzio, Luca ;
Pompili, Cecilia ;
Sabbatini, Armando .
RESPIRATION, 2010, 80 (03) :207-211
[3]  
Cataneo Daniele Cristina, 2007, J. bras. pneumol., V33, P128, DOI 10.1590/S1806-37132007000200005
[4]  
Corso SD, 2007, EUR RESPIR J, V29, P330
[5]   ATS statement: Guidelines for the six-minute walk test [J].
Crapo, RO ;
Casaburi, R ;
Coates, AL ;
Enright, PL ;
MacIntyre, NR ;
McKay, RT ;
Johnson, D ;
Wanger, JS ;
Zeballos, RJ ;
Bittner, V ;
Mottram, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) :111-117
[6]   Physiological response to the six-minute walk test in pulmonary arterial hypertension [J].
Deboeck, G ;
Niset, G ;
Vachiery, JL ;
Moraine, JJ ;
Naeije, R .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (04) :667-672
[7]   Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis [J].
Degano, Bruno ;
Sitbon, Olivier ;
Savale, Laurent ;
Garcia, Gilles ;
O'Callaghan, Dermot S. ;
Jais, Xavier ;
Humbert, Marc ;
Simonneau, Gerald .
CHEST, 2010, 137 (06) :1297-1303
[8]  
Dimopoulos Stavros, 2009, J Card Fail, V15, P882, DOI 10.1016/j.cardfail.2009.06.001
[9]  
Fox B, 2011, AM J RESP CRIT CARE, V183
[10]   The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect [J].
Frost, AE ;
Langleben, D ;
Oudiz, R ;
Hill, N ;
Horn, E ;
McLaughlin, V ;
Robbins, IM ;
Shapiro, S ;
Tapson, VF ;
Zwicke, D ;
DeMarco, T ;
Schilz, R ;
Rubenfire, M ;
Barst, RJ .
VASCULAR PHARMACOLOGY, 2005, 43 (01) :36-39